Multiple myeloma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BCMA 132
• CD38 22
• GPRC5D 35
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 4
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• AMPK 0
• B7-H3 0
• NRAS 1
• TIGIT 0
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 101+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.

  NCT06691685· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Updated 22 Jul 2026

  “The collaborator EsoBiotec was acquired by AstraZeneca.”Registry text, quoted unchanged. Source

• Terminated

  BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

  NCT04318327· Novartis Pharmaceuticals· Updated 9 Jul 2026

  “Business decision”Registry text, quoted unchanged. Source

• Terminated

  Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

  NCT05498545· Second Affiliated Hospital of Xi'an Jiaotong University· Updated 16 Jun 2026

  “Achieved the proof of concept”Registry text, quoted unchanged. Source

• Suspended

  CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

  NCT07340853· Thomas Martin, MD· Updated 11 Jun 2026

  “Safety Review”Registry text, quoted unchanged. Source

• Withdrawn

  Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment

  NCT07195617· Guangzhou Bio-gene Technology Co., Ltd· Updated 28 May 2026

  “Due to corporate strategic adjustment.”Registry text, quoted unchanged. Source

• Withdrawn

  BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma

  NCT07196124· Guangzhou Bio-gene Technology Co., Ltd· Updated 28 May 2026

  “Due to corporate strategic adjustment.”Registry text, quoted unchanged. Source

• Withdrawn

  UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

  NCT06698744· David Wald· Updated 13 May 2026

  “Replaced by study by different sponsor”Registry text, quoted unchanged. Source

• Suspended

  Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

  NCT06663046· Wondercel Biotech (ShenZhen)· Updated 7 May 2026

  “Because the implementation of the new regulation policy by the Chinese authority”Registry text, quoted unchanged. Source

• Withdrawn

  BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

  NCT05846737· Institute of Hematology & Blood Diseases Hospital, China· Updated 29 Apr 2026

  “The study was withdrawn due to the inability to enroll participants.”Registry text, quoted unchanged. Source

• Terminated

  MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

  NCT05090566· Pfizer· Updated 24 Apr 2026

  “A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

  NCT05828511· Regeneron Pharmaceuticals· Source

• A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Regeneron Pharmaceuticals· Source

• A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT07455851· Regeneron Pharmaceuticals· Source

• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  NCT05137054· Regeneron Pharmaceuticals· Source

• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Regeneron Pharmaceuticals· Source

• A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Regeneron Pharmaceuticals· Source

• Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03145181· Janssen Research & Development, LLC· Source

• A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

  NCT04133636· Janssen Research & Development, LLC· Source

• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

  NCT04923893· Janssen Research & Development, LLC· Source

• A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Janssen Research & Development, LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 16
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

See which targets of this disease your abstract mentions, and go to the people working on them.